Pneumococcal Polysaccharide
Isolation and characterization of human polyreactive pneumococcal polysaccharide antibodies
... against pneumococcal challenge. Polyreactive human pneumococcal polysaccha- ride IgG antibodies have not been extensively ...multiple pneumococcal poly- saccharides, including PPS14 and ...single ...
13
Evaluation of Previously Assigned Antibody Concentrations in Pneumococcal Polysaccharide Reference Serum 89SF by the Method of Cross-Standardization
... of pneumococcal disease in young children ...of pneumococcal infections in other ...Because pneumococcal conjugate vaccines prepared by different manufacturers using differing conjugation chemistries ...
6
Pneumococcal Type 22F Polysaccharide Absorption Improves the Specificity of a Pneumococcal-Polysaccharide Enzyme-Linked Immunosorbent Assay
... 23-valent pneumococcal-polysaccharide (PS) vaccine in healthy adults and to a pneumococcal conjugate vaccine in infants was examined by measuring immunoglob- ulin G (IgG) antibody titers by ...
7
Heterogeneity of the efficacy of the 23-valent pneumococcal polysaccharide vaccine caused by various underlying conditions of chronic pulmonary disease in older patients: prospective cohort study
... Previous pulmonary infection was highly associated with poor clinical prognosis. This finding suggests that beneficial PPV23 effectiveness might be unachievable for older people with chronic pulmonary disease in the ...
8
Is 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Combined With 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) Superior to PPSV23 Alone for Reducing Incidence or Severity of Pneumonia in Older Adults? A Clin-IQ
... 23-valent pneumococcal polysaccharide vaccine (PPSV23) and 13-valent pneumococcal conjugate vaccine ...of pneumococcal disease in the elderly ...
6
Specificity of the Antibody Response to the Pneumococcal Polysaccharide and Conjugate Vaccines in Human Immunodeficiency Virus-Infected Adults
... gous pneumococcal polysaccharide of serotype 22F at a final concentration of 16 g/ml, optimized for the lot number and assay used in the CDC laboratory ...
5
Triptych of the Hermit Saints: pneumococcal polysaccharide vaccines for the elderly
... of pneumococcal pneumonia remains ...warranted. Pneumococcal conjugate vaccination can prevent invasive and mucosal pneumococ- cal diseases in children and also in the ...
11
The effect of age on the response to the pneumococcal polysaccharide vaccine
... In this study, we evaluated the response to the vac- cine-related serotype Pn 6A. The prevaccine anti-Pn 6A antibody concentration seemed to be higher in the elderly, however after vaccination, the opsonic titer was ...
8
Pneumococcal Polysaccharide Immunization in Infants and Children
... shown that more than 90% of children between 1 and 12 years of age who were immunized with a 12-valent PPS vaccine developed a significant antibody response to most of the polysacchanide[r] ...
9
Decreased relative risk of pneumococcal pneumonia during the last decade, a nested case-control study
... of pneumococcal CAP have been found to be ...capsular polysaccharide antigen provide serotype-specific protection against serious infection, and the pneumococcal vaccines are designed to cover the ...
8
Would hemodialysis patients benefit from a Staphylococcus aureus vaccine?
... as pneumococcal polysaccharide vaccines, do elicit protective antibody titers in patients on hemodialysis, but titers decline more quickly over time than in healthy ...to pneumococcal poly- ...
8
Antibody Responses to Immunizations in Children with Type I Diabetes Mellitus: a Case-Control Study
... conjugated pneumococcal immunization more than 5 years ago had significantly higher pneumococcal antibody levels than children who did not have pneumococcal ...conjugated pneumococcal ...
5
Effectiveness of the polysaccharide pneumococcal vaccine among HIV infected persons in Brazil: a case control study
... Hospital of University of Campinas (HC UNICAMP), Hospital of São Paulo State Employee (HSPE) and Casa da AIDS of the University of São Paulo, all patients with documented HIV-infection receive care from special teams of ...
7
Previsit Planning Improves Pneumococcal Vaccination Rates in Childhood-Onset SLE
... for pneumococcal conjugate and pneumococcal polysaccharide vaccines in patients with c-SLE in the rheumatology clinic from January 2015 to August ...
11
Chemical characterization of Mycoplasma dispar capsule and a study of its immune responses in calves and mice
... Activation of antigen specific suppressor T cells by B cells from mice immunized with type 111 pneumococcal polysaccharide.. and Baker, P.J.[r] ...
109
Recurrent severe invasive pneumococcal disease in an adult with previously unknown hyposplenia
... Table 2 Recommended immunizations against invasive pneumococcal disease using the 13-valent pneumococcal conjugate vaccine PCV13 and the 23-valent pneumococcal polysaccharide vaccine PPV[r] ...
7
Pneumococcal Capsular Polysaccharide Preparations May Contain Non-C-Polysaccharide Contaminants That Are Immunogenic
... the three postvaccination sera (P23B, P4B, and P3B) with C-PS and then performed the ELISA for anti-6B antibody in the presence of varying concentrations of different PSs in so- lution (Fig. 3). With the control serum ...
6
Development and Characterization of a Multiplex Bead-Based Immunoassay To Quantify Pneumococcal Capsular Polysaccharide-Specific Antibodies
... A number of immunoassays have been developed to measure the concentration of serotype (St)-specific human IgG anti- pneumococcal (anti-Pn) capsular polysaccharide (Ps) antibodies following induced and ...
7
Detection of Pneumococcal Capsular polysaccharide antigens by latex agglutination, counterimmunoelectrophoresis, and radioimmunoassay in middle ear exudates in acute otitis media
... Detection of Pneumococcal Capsular Polysaccharide Antigens by Latex Agglutination, Counterimmunoelectrophoresis, and Radioimmunoassay in Middle Ear Exudates in Acute Otitis Media MAIJA K[r] ...
6
Pneumonia immunization in older adults: review of vaccine effectiveness and strategies
... clinical efficacy of PCV13 against pneumococcal pneumonia in adults $ 65 years of age had not been demonstrated. As part of the Accelerated Approval regulation process, Pfizer has agreed to conduct further studies ...
9